Clinical trial
Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections Who Have no Other Treatment Options
Name
EAP to Fosmanogepix
Description
The EAP is intended to provide a treatment option for patients with proven or probable serious or life-threatening invasive fungal infection (in accordance with the EORTC-MSGERC criteria) who have exhausted their treatment options, primarily due to an infection with a resistant fungal pathogen, and for whom no other treatment options are available through marketed drugs or investigational agents in clinical studies ongoing in the respective indication.
Trial arms
Treatment
Fosmanogepix solution for infusion
Fosmanogepix solution for infusion, 20 mg/mL for intravenous administration
Fosmanogepix 400 mg tablets
Fosmanogepix 400 mg tablets for oral administration
Size
-1
Eligibility criteria
The EAP is intended to provide a treatment option for patients with proven or probable serious or life-threatening invasive fungal infection (in accordance with the EORTC-MSGERC criteria) who have exhausted their treatment options, primarily due to an infection with a resistant fungal pathogen, and for whom no other treatment options are available through marketed drugs or investigational agents in clinical studies ongoing in the respective indication.
Protocol
{'studyType': 'EXPANDED_ACCESS', 'expandedAccessTypes': {'individual': True}}
Updated at
2024-05-29
1 organization
1 product
1 indication
Organization
Basilea PharmaceuticaProduct
FosmanogepixIndication
Invasive Fungal Infections